CoChat

The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells

Allday, Martin J., Bazot, Quentin, White, Robert E. · 2015 · Current Topics in Microbiology and Immunology
Cited by 27

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/978-3-319-22834-1_3

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 190

  1. Acosta JC, Gil J (2012) Senescence: a new weapon for cancer therapy. Trends Cell Biol 22:211–219 · DOI · Paper page
  2. Allday MJ (2013) EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection. Front Genet 4:212 · DOI
  3. Allday MJ, Crawford DH, Griffin BE (1988) Prediction and demonstration of a novel Epstein-Barr virus nuclear antigen. Nucleic Acids Res 16:4353–4367 · doi:10.1093/nar/16.10.4353
  4. Allday MJ, Crawford DH, Griffin BE (1989) Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol 70(Pt 7):1755–1764 · DOI
  5. Allday MJ, Farrell PJ (1994) Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 68:3491–3498 · DOI
  6. Altmann M, Hammerschmidt W (2005) Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol 3:e404 · DOI · Paper page
  7. Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt’s lymphoma. Oncogene 27:421–433 · DOI · Paper page
  8. Arvey A, Tempera I, Tsai K, Chen HS, Tikhmyanova N, Klichinsky M, Leslie C, Lieberman PM (2012) An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12:233–245 · DOI · Paper page
  9. Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA (1999) Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 190:567–576 · doi:10.1084/jem.190.4.567
  10. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA (1998) EBV persistence in memory B cells in vivo. Immunity 9:395–404 · DOI · Paper page
  11. Babcock GJ, Hochberg D, Thorley-Lawson AD (2000) The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13:497–506 · DOI
  12. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C et al (1984) DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310:207–211 · DOI · Paper page
  13. Bain M, Watson RJ, Farrell PJ, Allday MJ (1996) Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol 70:2481–2489 · DOI
  14. Bajaj BG, Murakami M, Cai Q, Verma SC, Lan K, Robertson ES (2008) Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol 82:4082–4090 · DOI
  15. Banerjee S, Lu J, Cai Q, Saha A, Jha HC, Dzeng RK, Robertson ES (2013) The EBV latent antigen 3C inhibits apoptosis through targeted regulation of interferon regulatory factors 4 and 8. PLoS Pathog 9:e1003314 · DOI
  16. Barolo S, Stone T, Bang AG, Posakony JW (2002) Default repression and Notch signaling: hairless acts as an adaptor to recruit the corepressors Groucho and dCtBP to suppressor of hairless. Genes Dev 16:1964–1976 · DOI · Paper page
  17. Bazot Q, Deschamps T, Tafforeau L, Siouda M, Leblanc P, Harth-Hertle ML, Rabourdin-Combe C, Lotteau V, Kempkes B, Tommasino M, Gruffat H, Manet E (2014) Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1. Nucleic Acids Res 42:9700–9716 · DOI
  18. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315–326 · DOI · Paper page
  19. Bourillot PY, Waltzer L, Sergeant A, Manet E (1998) Transcriptional repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does not require RBP-Jkappa. J Gen Virol 79(Pt 2):363–370 · doi:10.1099/0022-1317-79-2-363
  20. Brown AC, Baigent SJ, Smith LP, Chattoo JP, Petherbridge LJ, Hawes P, Allday MJ, Nair V (2006) Interaction of MEQ protein and C-terminal-binding protein is critical for induction of lymphomas by Marek’s disease virus. Proc Natl Acad Sci USA 103:1687–1692 · doi:10.1073/pnas.0507595103
  21. Buck M, Burgess A, Stirzaker R, Krauer K, Sculley T (2006) Epstein-Barr virus nuclear antigen 3A contains six nuclear-localization signals. J Gen Virol 87:2879–2884 · doi:10.1099/vir.0.81927-0
  22. Burgess A, Buck M, Krauer K, Sculley T (2006) Nuclear localization of the Epstein-Barr virus EBNA3B protein. J Gen Virol 87:789–793 · doi:10.1099/vir.0.81640-0
  23. Cai Q, Guo Y, Xiao B, Banerjee S, Saha A, Lu J, Glisovic T, Robertson ES (2011) Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog 7:e1002418 · DOI
  24. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, Raab-Traub N, Cullen BR (2006) Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2:e23 · DOI · Paper page
  25. Calderwood MA, Lee S, Holthaus AM, Blacklow SC, Kieff E, Johannsen E (2011) Epstein-Barr virus nuclear protein 3C binds to the N-terminal (NTD) and beta trefoil domains (BTD) of RBP/CSL; only the NTD interaction is essential for lymphoblastoid cell growth. Virology 414:19–25 · DOI
  26. Campos EI, Stafford JM, Reinberg D (2014) Epigenetic inheritance: histone bookmarks across generations. Trends Cell Biol 24:664–674 · DOI · Paper page
  27. Chen A, Divisconte M, Jiang X, Quink C, Wang F (2005) Epstein-Barr virus with the latent infection nuclear antigen 3B completely deleted is still competent for B-cell growth transformation in vitro. J Virol 79:4506–4509 · doi:10.1128/jvi.79.7.4506-4509.2005
  28. Chen A, Zhao B, Kieff E, Aster JC, Wang F (2006) EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 80:10139–10150 · DOI
  29. Chinnadurai G (2007) Transcriptional regulation by C-terminal binding proteins. Int J Biochem Cell Biol 39:1593–1607 · DOI · Paper page
  30. Choudhuri T, Verma SC, Lan K, Murakami M, Robertson ES (2007) The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol 81:6718–6730 · DOI
  31. Choudhuri T, Verma SC, Lan K, Robertson ES (2006) Expression of alpha V integrin is modulated by Epstein-Barr virus nuclear antigen 3C and the metastasis suppressor Nm23-H1 through interaction with the GATA-1 and Sp1 transcription factors. Virology 351:58–72 · doi:10.1016/j.virol.2006.03.031
  32. Cludts I, Farrell PJ (1998) Multiple functions within the Epstein-Barr virus EBNA-3A protein. J Virol 72:1862–1869 · doi:10.1128/jvi.72.3.1862-1869.1998
  33. Cooper A, Johannsen E, Maruo S, Cahir-McFarland E, Illanes D, Davidson D, Kieff E (2003) EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth. J Virol 77:999–1010 · doi:10.1128/jvi.77.2.999-1010.2003
  34. Cotter MA 2nd, Robertson ES (2000) Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol 20:5722–5735 · DOI
  35. Crawford DH (2001) Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 356:461–473 · DOI · Paper page
  36. Dalbies-Tran R, Stigger-Rosser E, Dotson T, Sample CE (2001) Amino acids of Epstein-Barr virus nuclear antigen 3A essential for repression of Jkappa-mediated transcription and their evolutionary conservation. J Virol 75:90–99 · doi:10.1128/jvi.75.1.90-99.2001
  37. Dang CV, O’Donnell KA, Juopperi T (2005) The great MYC escape in tumorigenesis. Cancer Cell 8:177–178 · DOI
  38. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, Young LS (1993) Epstein-Barr virus and Hodgkin’s disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 177:339–349 · DOI · Paper page
  39. Delecluse HJ, Hilsendegen T, Pich D, Zeidler R, Hammerschmidt W (1998) Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci USA 95:8245–8250 · DOI · Paper page
  40. Egle A, Harris AW, Bouillet P, Cory S (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101:6164–6169 · DOI · Paper page
  41. Ehlers B, Ochs A, Leendertz F, Goltz M, Boesch C, Matz-Rensing K (2003) Novel simian homologues of Epstein-Barr virus. J Virol 77:10695–10699 · doi:10.1128/jvi.77.19.10695-10699.2003
  42. Ehlers B, Spiess K, Leendertz F, Peeters M, Boesch C, Gatherer D, McGeoch DJ (2010) Lymphocryptovirus phylogeny and the origins of Epstein-Barr virus. J Gen Virol 91:630–642 · DOI
  43. Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, Cox J, Pye D, Moss DJ, Bharadwaj M (2008) Phase I trial of a CD8+T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82:1448–1457 · DOI
  44. Epstein MA (2001) Historical background. Philos Trans R Soc Lond B Biol Sci 356:413–420 · DOI
  45. Feederle R, Bartlett EJ, Delecluse HJ (2010) Epstein-Barr virus genetics: talking about the BAC generation. Herpesviridae 1:6 · doi:10.1186/2042-4280-1-6
  46. Fischer SF, Bouillet P, O’Donnell K, Light A, Tarlinton DM, Strasser A (2007) Proapoptotic BH3-only protein Bim is essential for developmentally programmed death of germinal center-derived memory B cells and antibody-forming cells. Blood 110:3978–3984 · DOI · Paper page
  47. Garrido JL, Maruo S, Takada K, Rosendorff A (2009) EBNA3C interacts with Gadd34 and counteracts the unfolded protein response. Virol J 6:231 · doi:10.1186/1743-422x-6-231
  48. Gorzer I, Niesters HG, Cornelissen JJ, Puchhammer-Stockl E (2006) Characterization of Epstein-Barr virus Type I variants based on linked polymorphism among EBNA3A, -3B, and -3C genes. Virus Res 118:105–114 · doi:10.1016/j.virusres.2005.11.020
  49. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE, Rooney CM (2001) An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97:835–843 · DOI · Paper page
  50. Gruhne B, Sompallae R, Masucci MG (2009) Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene 28:3997–4008 · DOI · Paper page
  51. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S (2012) The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 13:654–666 · DOI · Paper page
  52. Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319:1352–1355 · DOI · Paper page
  53. Harth-Hertle ML, Scholz BA, Erhard F, Glaser LV, Dolken L, Zimmer R, Kempkes B (2013) Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9. PLoS Pathog 9:e1003638 · DOI
  54. Hawkins JB, Delgado-Eckert E, Thorley-Lawson DA, Shapiro M (2013) The cycle of EBV infection explains persistence, the sizes of the infected cell populations and which come under CTL regulation. PLoS Pathog 9:e1003685 · DOI
  55. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW (2005) Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436:807–811 · DOI · Paper page
  56. Hennessy K, Fennewald S, Kieff E (1985) A third viral nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. Proc Natl Acad Sci USA 82:5944–5948 · doi:10.1073/pnas.82.17.5944
  57. Hennessy K, Wang F, Bushman EW, Kieff E (1986) Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci USA 83:5693–5697 · doi:10.1073/pnas.83.15.5693
  58. Hertle ML, Popp C, Petermann S, Maier S, Kremmer E, Lang R, Mages J, Kempkes B (2009) Differential gene expression patterns of EBV infected EBNA-3A positive and negative human B lymphocytes. PLoS Pathog 5:e1000506 · DOI
  59. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925–935 · DOI · Paper page
  60. Hickabottom M, Parker GA, Freemont P, Crook T, Allday MJ (2002) Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J Biol Chem 277:47197–47204 · DOI
  61. Humeniuk R, Rosu-Myles M, Fares J, Koller R, Bies J, Wolff L (2013) The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate. Blood Cancer J 3:e99 · DOI
  62. Isaksson A, Berggren M, Ricksten A (2003) Epstein-Barr virus U leader exon contains an internal ribosome entry site. Oncogene 22:572–581 · doi:10.1038/sj.onc.1206149
  63. Jha HC, Aj MP, Saha A, Banerjee S, Lu J, Robertson ES (2014) Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression. J Virol 88:3776–3788 · DOI
  64. Jha HC, Lu J, Saha A, Cai Q, Banerjee S, Prasad MA, Robertson ES (2013) EBNA3C-mediated regulation of aurora kinase B contributes to Epstein-Barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases. J Virol 87:12121–12138 · DOI
  65. Jiang H, Cho YG, Wang F (2000) Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus. J Virol 74:5921–5932 · DOI
  66. Jiang S, Willox B, Zhou H, Holthaus AM, Wang A, Shi TT, Maruo S, Kharchenko PV, Johannsen EC, Kieff E, Zhao B (2014) Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A. Proc Natl Acad Sci USA 111:421–426 · DOI
  67. Jimenez-Ramirez C, Brooks AJ, Forshell LP, Yakimchuk K, Zhao B, Fulgham TZ, Sample CE (2006) Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter. J Virol 80:11200–11208 · DOI
  68. Johannsen E, Miller CL, Grossman SR, Kieff E (1996) EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. J Virol 70:4179–4183 · doi:10.1128/jvi.70.6.4179-4183.1996
  69. Joseph AM, Babcock GJ, Thorley-Lawson DA (2000) Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol 74:9964–9971 · doi:10.1128/jvi.74.21.9964-9971.2000
  70. Kashuba E, Yurchenko M, Yenamandra SP, Snopok B, Isaguliants M, Szekely L, Klein G (2008) EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes. Proc Natl Acad Sci USA 105:5489–5494 · DOI
  71. Kaul R, Verma SC, Murakami M, Lan K, Choudhuri T, Robertson ES (2006) Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1. J Virol 80:1321–1331 · DOI
  72. Kelly G, Bell A, Rickinson A (2002) Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 8:1098–1104 · DOI · Paper page
  73. Kelly GL, Long HM, Stylianou J, Thomas WA, Leese A, Bell AI, Bornkamm GW, Mautner J, Rickinson AB, Rowe M (2009) An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in burkitt lymphomagenesis: the Wp/BHRF1 link. PLoS Pathog 5:e1000341 · DOI · Paper page
  74. Kelly GL, Stylianou J, Rasaiyaah J, Wei W, Thomas W, Croom-Carter D, Kohler C, Spang R, Woodman C, Kellam P, Rickinson AB, Bell AI (2013) Different patterns of Epstein-Barr virus latency in endemic Burkitt lymphoma (BL) lead to distinct variants within the BL-associated gene expression signature. J Virol 87:2882–2894 · DOI
  75. Khanna R, Burrows SR, Kurilla MG, Jacob CA, Misko IS, Sculley TB, Kieff E, Moss DJ (1992) Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med 176:169–176 · DOI · Paper page
  76. Khanna R, Slade RW, Poulsen L, Moss DJ, Burrows SR, Nicholls J, Burrows JM (1997) Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol 71:8340–8346 · doi:10.1128/jvi.71.11.8340-8346.1997
  77. Kheradmand Kia S, Solaimani Kartalaei P, Farahbakhshian E, Pourfarzad F, von Lindern M, Verrijzer CP (2009) EZH2-dependent chromatin looping controls INK4a and INK4b, but not ARF, during human progenitor cell differentiation and cellular senescence. Epigenetics Chromatin 2:16 · DOI
  78. Kienzle N, Young DB, Liaskou D, Buck M, Greco S, Sculley TB (1999) Intron retention may regulate expression of Epstein-Barr virus nuclear antigen 3 family genes. J Virol 73:1195–1204 · doi:10.1128/jvi.73.2.1195-1204.1999
  79. Kim SM, Kang SH, Lee WK (2006) Identification of two types of naturally-occurring intertypic recombinants of Epstein-Barr virus. Mol Cells 21:302–307 · doi:10.1016/s1016-8478(23)12894-9
  80. Kis LL, Takahara M, Nagy N, Klein G, Klein E (2006) Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett 104:83–88 · doi:10.1016/j.imlet.2005.11.003
  81. Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, Spits H, Klein G, Klein E (2010) IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proc Natl Acad Sci USA 107:872–877 · doi:10.1073/pnas.0912920107
  82. Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG (1998) p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt’s lymphoma. Blood 91:1680–1687 · DOI
  83. Knight JS, Lan K, Subramanian C, Robertson ES (2003) Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77:4261–4272 · DOI
  84. Knight JS, Robertson ES (2004) Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol 78:1981–1991 · DOI
  85. Knight JS, Sharma N, Kalman DE, Robertson ES (2004) A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol 78:12857–12867 · doi:10.1128/jvi.78.23.12857-12867.2004
  86. Knight JS, Sharma N, Robertson ES (2005a) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci USA 102:18562–18566 · DOI · Paper page
  87. Knight JS, Sharma N, Robertson ES (2005b) SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 25:1749–1763 · DOI
  88. Kohlhof H, Hampel F, Hoffmann R, Burtscher H, Weidle UH, Holzel M, Eick D, Zimber-Strobl U, Strobl LJ (2009) Notch1, Notch2, and Epstein-Barr virus-encoded nuclear antigen 2 signaling differentially affects proliferation and survival of Epstein-Barr virus-infected B cells. Blood 113:5506–5515 · doi:10.1182/blood-2008-11-190090
  89. Krauer K, Buck M, Flanagan J, Belzer D, Sculley T (2004a) Identification of the nuclear localization signals within the Epstein-Barr virus EBNA-6 protein. J Gen Virol 85:165–172 · DOI
  90. Krauer KG, Buck M, Belzer DK, Flanagan J, Chojnowski GM, Sculley TB (2004b) The Epstein-Barr virus nuclear antigen-6 protein co-localizes with EBNA-3 and survival of motor neurons protein. Virology 318:280–294 · doi:10.1016/j.virol.2003.09.032
  91. Le Roux A, Berebbi M, Moukaddem M, Perricaudet M, Joab I (1993) Identification of a short amino acid sequence essential for efficient nuclear targeting of the Epstein-Barr virus nuclear antigen 3A. J Virol 67:1716–1720 · doi:10.1128/jvi.67.3.1716-1720.1993
  92. Le Roux A, Kerdiles B, Walls D, Dedieu JF, Perricaudet M (1994) The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology 205:596–602 · doi:10.1006/viro.1994.1687
  93. Lee S, Sakakibara S, Maruo S, Zhao B, Calderwood MA, Holthaus AM, Lai CY, Takada K, Kieff E, Johannsen E (2009) Epstein-Barr virus nuclear protein 3C domains necessary for lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J Virol 83:12368–12377 · DOI
  94. Lin J, Johannsen E, Robertson E, Kieff E (2002) Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J Virol 76:232–242 · doi:10.1128/jvi.76.1.232-242.2002
  95. Lowe SW, Cepero E, Evan G (2004) Intrinsic tumour suppression. Nature 432:307–315 · DOI · Paper page
  96. Maruo S, Johannsen E, Illanes D, Cooper A, Kieff E (2003) Epstein-Barr virus nuclear protein EBNA3A is critical for maintaining lymphoblastoid cell line growth. J Virol 77:10437–10447 · doi:10.1128/jvi.77.19.10437-10447.2003
  97. Maruo S, Johannsen E, Illanes D, Cooper A, Zhao B, Kieff E (2005) Epstein-Barr virus nuclear protein 3A domains essential for growth of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1 is critical. J Virol 79:10171–10179 · DOI
  98. Maruo S, Wu Y, Ishikawa S, Kanda T, Iwakiri D, Takada K (2006) Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci USA 103:19500–19505 · DOI · Paper page
  99. Maruo S, Wu Y, Ito T, Kanda T, Kieff ED, Takada K (2009) Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth. Proc Natl Acad Sci USA 106:4419–4424 · doi:10.1073/pnas.0813134106
  100. Maruo S, Zhao B, Johannsen E, Kieff E, Zou J, Takada K (2011) Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci USA 108:1919–1924 · DOI
  101. McAulay KA, Haque T, Urquhart G, Bellamy C, Guiretti D, Crawford DH (2009) Epitope specificity and clonality of EBV-specific CTLs used to treat posttransplant lymphoproliferative disease. J Immunol 182:3892–3901 · DOI
  102. McClellan MJ, Khasnis S, Wood CD, Palermo RD, Schlick SN, Kanhere AS, Jenner RG, West MJ (2012) Downregulation of integrin receptor-signaling genes by Epstein-Barr virus EBNA 3C via promoter-proximal and -distal binding elements. J Virol 86:5165–5178 · doi:10.1128/jvi.07161-11
  103. McClellan MJ, Wood CD, Ojeniyi O, Cooper TJ, Kanhere A, Arvey A, Webb HM, Palermo RD, Harth-Hertle ML, Kempkes B, Jenner RG, West MJ (2013) Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS Pathog 9:e1003636 · DOI
  104. Midgley RS, Bell AI, McGeoch DJ, Rickinson AB (2003) Latent gene sequencing reveals familial relationships among Chinese Epstein-Barr virus strains and evidence for positive selection of A11 epitope changes. J Virol 77:11517–11530 · DOI
  105. Midgley RS, Blake NW, Yao QY, Croom-Carter D, Cheung ST, Leung SF, Chan AT, Johnson PJ, Huang D, Rickinson AB, Lee SP (2000) Novel intertypic recombinants of epstein-barr virus in the chinese population. J Virol 74:1544–1548 · doi:10.1128/jvi.74.3.1544-1548.2000
  106. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J (2010) Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138:1429–1440 · DOI · Paper page
  107. Morel V, Lecourtois M, Massiani O, Maier D, Preiss A, Schweisguth F (2001) Transcriptional repression by suppressor of hairless involves the binding of a hairless-dCtBP complex in Drosophila. Curr Biol 11:789–792 · DOI · Paper page
  108. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med 176:157–168 · DOI · Paper page
  109. Nagy E, Veress G, Szarka K, Csoma E, Beck Z (2005) Frequent methylation of p16INK4A/p14ARF promoters in tumorigenesis of Epstein-Barr virus transformed lymphoblastoid cell lines. Anticancer Res 25:2153–2160
  110. Nagy N, Adori M, Rasul A, Heuts F, Salamon D, Ujvari D, Madapura HS, Leveau B, Klein G, Klein E (2012) Soluble factors produced by activated CD4+T cells modulate EBV latency. Proc Natl Acad Sci USA 109:1512–1517 · doi:10.1073/pnas.1120587109
  111. Naumova N, Smith EM, Zhan Y, Dekker J (2012) Analysis of long-range chromatin interactions using chromosome conformation capture. Methods 58:192–203 · DOI · Paper page
  112. Nguyen-Van D, Keane C, Han E, Jones K, Nourse JP, Vari F, Ross N, Crooks P, Ramuz O, Green M, Griffith L, Trappe R, Grigg A, Mollee P, Gandhi MK (2011) Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. Am J Blood Res 1:146–159
  113. Nikiforow S, Lacasce AS (2014) Targeting Epstein-Barr virus-associated lymphomas. J Clin Oncol 32:830–832 · doi:10.1200/jco.2013.53.2994
  114. Nikitin PA, Luftig MA (2012) The DNA damage response in viral-induced cellular transformation. Br J Cancer 106:429–435 · DOI
  115. Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, White RE, Allday MJ, Patel A, Dave SS, Kim W, Hu K, Guo J, Tainter D, Rusyn E, Luftig MA (2010) An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 8:510–522 · DOI · Paper page
  116. O’Nions J, Turner A, Craig R, Allday MJ (2006) Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53. J Virol 80:12408–12413 · DOI
  117. Palmero I, Holder A, Sinclair AJ, Dickson C, Peters G (1993) Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene 8:1049–1054
  118. Parker GA, Crook T, Bain M, Sara EA, Farrell PJ, Allday MJ (1996) Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13:2541–2549
  119. Parker GA, Touitou R, Allday MJ (2000) Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19:700–709 · DOI
  120. Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ (2012) BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 40:7233–7246 · DOI
  121. Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5:e1000492 · DOI · Paper page
  122. Peng R, Moses SC, Tan J, Kremmer E, Ling PD (2005) The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter. J Virol 79:4492–4505 · doi:10.1128/jvi.79.7.4492-4505.2005
  123. Petti L, Kieff E (1988) A sixth Epstein-Barr virus nuclear protein (EBNA3B) is expressed in latently infected growth-transformed lymphocytes. J Virol 62:2173–2178 · doi:10.1128/jvi.62.6.2173-2178.1988
  124. Petti L, Sample C, Kieff E (1990) Subnuclear localization and phosphorylation of Epstein-Barr virus latent infection nuclear proteins. Virology 176:563–574 · DOI
  125. Petti L, Sample J, Wang F, Kieff E (1988) A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol 62:1330–1338 · doi:10.1128/jvi.62.4.1330-1338.1988
  126. Pokrovskaja K, Ehlin-Henriksson B, Bartkova J, Bartek J, Scuderi R, Szekely L, Wiman KG, Klein G (1996) Phenotype-related differences in the expression of D-type cyclins in human B cell-derived lines. Cell Growth Differ 7:1723–1732
  127. Price AM, Tourigny JP, Forte E, Salinas RE, Dave SS, Luftig MA (2012) Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-kappaB activation. J Virol 86:11096–11106 · DOI
  128. Radkov SA, Bain M, Farrell PJ, West M, Rowe M, Allday MJ (1997) Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol 71:8552–8562 · DOI
  129. Radkov SA, Touitou R, Brehm A, Rowe M, West M, Kouzarides T, Allday MJ (1999) Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73:5688–5697 · DOI
  130. Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X, Calasanz MJ, Panizo C, Richter JA, Hernandez JM, Roman-Gomez J, Prosper F, Martinez-Climent JA (2010) Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116:2531–2542 · DOI · Paper page
  131. Ricksten A, Kallin B, Alexander H, Dillner J, Fahraeus R, Klein G, Lerner R, Rymo L (1988) BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci USA 85:995–999 · doi:10.1073/pnas.85.4.995
  132. Rivailler P, Cho YG, Wang F (2002) Complete genomic sequence of an Epstein-Barr virus-related herpesvirus naturally infecting a new world primate: a defining point in the evolution of oncogenic lymphocryptoviruses. J Virol 76:12055–12068 · DOI
  133. Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, Tomkinson B, Kieff E (1995) Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol 69:3108–3116 · DOI · Paper page
  134. Robertson ES, Lin J, Kieff E (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 70:3068–3074 · doi:10.1128/jvi.70.5.3068-3074.1996
  135. Rochford R, Hobbs MV, Garnier JL, Cooper NR, Cannon MJ (1993) Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci USA 90:352–356 · DOI
  136. Rosendorff A, Illanes D, David G, Lin J, Kieff E, Johannsen E (2004) EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J Virol 78:367–377 · DOI
  137. Roughan JE, Thorley-Lawson DA (2009) The intersection of Epstein-Barr virus with the germinal center. J Virol 83:3968–3976 · doi:10.1128/jvi.02609-08
  138. Saha A, Bamidele A, Murakami M, Robertson ES (2011) EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 85:2079–2088 · DOI
  139. Saha A, Lu J, Morizur L, Upadhyay SK, Aj MP, Robertson ES (2012) E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog 8:e1002573 · DOI
  140. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83:4652–4669 · DOI
  141. Salamon D, Adori M, Ujvari D, Wu L, Kis LL, Madapura HS, Nagy N, Klein G, Klein E (2012) Latency type-dependent modulation of Epstein-Barr virus-encoded latent membrane protein 1 expression by type I interferons in B cells. J Virol 86:4701–4707 · doi:10.1128/jvi.06829-11
  142. Sample C, Parker B (1994) Biochemical characterization of Epstein-Barr virus nuclear antigen 3A and 3C proteins. Virology 205:534–539 · doi:10.1006/viro.1994.1675
  143. Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A (1990) Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 64:4084–4092 · DOI · Paper page
  144. Sewalt RG, Gunster MJ, van der Vlag J, Satijn DP, Otte AP (1999) C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins. Mol Cell Biol 19:777–787 · DOI · Paper page
  145. Shannon-Lowe C, Baldwin G, Feederle R, Bell A, Rickinson A, Delecluse HJ (2005) Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J Gen Virol 86:3009–3019 · DOI
  146. Sherr CJ (2012) Ink4-arf locus in cancer and aging. Wiley Interdiscip Rev Dev Biol 1:731–741 · DOI · Paper page
  147. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119:941–953 · DOI · Paper page
  148. Shi Y, Sawada J, Sui G, el Affar B, Whetstine JR, Lan F, Ogawa H, Luke MP, Nakatani Y, Shi Y (2003) Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422:735–738 · DOI · Paper page
  149. Siemer D, Kurth J, Lang S, Lehnerdt G, Stanelle J, Kuppers R (2008) EBV transformation overrides gene expression patterns of B cell differentiation stages. Mol Immunol 45:3133–3141 · DOI
  150. Sinclair AJ, Palmero I, Peters G, Farrell PJ (1994) EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J 13:3321–3328 · DOI · Paper page
  151. Skalska L, White RE, Franz M, Ruhmann M, Allday MJ (2010) Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6:e1000951 · DOI · Paper page
  152. Skalska L, White RE, Parker GA, Sinclair AJ, Paschos K, Allday MJ (2013) Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog 9:e1003187 · DOI · Paper page
  153. Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M, Packham G, Farrell PJ (1999) Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol 73:4678–4688 · DOI
  154. Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB (1996) Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 184:1801–1813 · DOI · Paper page
  155. Strasser A (2005) The role of BH3-only proteins in the immune system. Nat Rev Immunol 5:189–200 · DOI · Paper page
  156. Strowig T, Gurer C, Ploss A, Liu YF, Arrey F, Sashihara J, Koo G, Rice CM, Young JW, Chadburn A, Cohen JI, Munz C (2009) Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med 206:1423–1434 · DOI · Paper page
  157. Subramanian C, Cotter MA 2nd, Robertson ES (2001) Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat Med 7:350–355 · DOI
  158. Sundqvist A, Sollerbrant K, Svensson C (1998) The carboxy-terminal region of adenovirus E1A activates transcription through targeting of a C-terminal binding protein-histone deacetylase complex. FEBS Lett 429:183–188 · DOI
  159. Tempera I, Lieberman PM (2014) Epigenetic regulation of EBV persistence and oncogenesis. Semin Cancer Biol 26:22–29 · DOI
  160. Thorley-Lawson DA, Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt’s lymphoma. Nat Rev Microbiol 6:913–924 · DOI · Paper page
  161. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328–1337 · DOI · Paper page
  162. Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M (2013) The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol · DOI · Paper page
  163. Thorley-Lawson DA, Strominger JL (1978) Reversible inhibition by phosphonoacetic acid of human B lymphocyte transformation by Epstein-Barr virus. Virology 86:423–431 · doi:10.1016/0042-6822(78)90082-x
  164. Tomkinson B, Kieff E (1992a) Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection. J Virol 66:780–789 · doi:10.1128/jvi.66.2.780-789.1992
  165. Tomkinson B, Kieff E (1992b) Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol 66:2893–2903 · doi:10.1128/jvi.66.5.2893-2903.1992
  166. Tomkinson B, Robertson E, Kieff E (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 67:2014–2025 · DOI · Paper page
  167. Touitou R, Arbach H, Cochet C, Feuillard J, Martin A, Raphael M, Joab I (2003) Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt’s lymphoma cell lines. J Gen Virol 84:949–957 · DOI
  168. Touitou R, Hickabottom M, Parker G, Crook T, Allday MJ (2001) Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J Virol 75:7749–7755 · DOI
  169. Touitou R, O’Nions J, Heaney J, Allday MJ (2005) Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol 86:1269–1277 · DOI
  170. Vereide DT, Sugden B (2011) Lymphomas differ in their dependence on Epstein-Barr virus. Blood 117:1977–1985 · DOI
  171. Waltzer L, Perricaudet M, Sergeant A, Manet E (1996) Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol 70:5909–5915 · doi:10.1128/jvi.70.9.5909-5915.1996
  172. Watanabe A, Maruo S, Ito T, Ito M, Katsumura KR, Takada K (2010) Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1. J Virol 84:2893–2901 · DOI
  173. West MJ (2006) Structure and function of the Epstein-Barr virus transcription factor, EBNA 3C. Curr Protein Pept Sci 7:123–136 · doi:10.2174/138920306776359777
  174. West MJ, Webb HM, Sinclair AJ, Woolfson DN (2004) Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C. J Virol 78:9431–9445 · DOI
  175. White RE, Groves IJ, Turro E, Yee J, Kremmer E, Allday MJ (2010) Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS ONE 5:e13979 · DOI
  176. White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C, Savoldo B, Coutinho R, Bodor C, Gribben J, Ibrahim HA, Bower M, Nourse JP, Gandhi MK, Middeldorp J, Cader FZ, Murray P, Munz C, Allday MJ (2012) EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 122:1487–1502 · DOI · Paper page
  177. Yao QY, Rowe M, Martin B, Young LS, Rickinson AB (1991) The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. J Gen Virol 72(Pt 7):1579–1590 · DOI
  178. Yee J, White RE, Anderton E, Allday MJ (2011) Latent Epstein-Barr virus can inhibit apoptosis in B cells by blocking the induction of NOXA expression. PLoS ONE 6:e28506 · DOI
  179. Yenamandra SP, Sompallae R, Klein G, Kashuba E (2009) Comparative analysis of the Epstein-Barr virus encoded nuclear proteins of EBNA-3 family. Comput Biol Med 39:1036–1042 · DOI
  180. Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q, Choudhuri T, Robertson ES (2009) Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388:236–247 · DOI
  181. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 69(Pt 5):1051–1065 · doi:10.1099/0022-1317-69-5-1051
  182. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4:757–768 · DOI · Paper page
  183. Young LS, Yao QY, Rooney CM, Sculley TB, Moss DJ, Rupani H, Laux G, Bornkamm GW, Rickinson AB (1987) New type B isolates of Epstein-Barr virus from Burkitt’s lymphoma and from normal individuals in endemic areas. J Gen Virol 68(Pt 11):2853–2862 · DOI · Paper page
  184. Young P, Anderton E, Paschos K, White R, Allday MJ (2008) Epstein-Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts with a subset of chaperones and co-chaperones. J Gen Virol 89:866–877 · DOI
  185. Zhang Q, Wang SY, Nottke AC, Rocheleau JV, Piston DW, Goodman RH (2006) Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc Natl Acad Sci USA 103:9029–9033 · DOI · Paper page
  186. Zhao B, Dalbies-Tran R, Jiang H, Ruf IK, Sample JT, Wang F, Sample CE (2003) Transcriptional regulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses. J Virol 77:5639–5648 · doi:10.1128/jvi.77.10.5639-5648.2003
  187. Zhao B, Mar JC, Maruo S, Lee S, Gewurz BE, Johannsen E, Holton K, Rubio R, Takada K, Quackenbush J, Kieff E (2011) Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci USA 108:337–342 · DOI
  188. Zhao B, Sample CE (2000) Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J Virol 74:5151–5160 · DOI
  189. Zhao LJ, Subramanian T, Vijayalingam S, Chinnadurai G (2014) CtBP2 proteome: role of CtBP in E2F7-mediated repression and cell proliferation. Genes Cancer 5:31–40 · DOI
  190. Zimber-Strobl U, Strobl LJ (2001) EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin Cancer Biol 11:423–434 · DOI

Cited by

See all 27

Metadata

Authors
Allday, M. J., Bazot, Q., & White, R. E.
Venue
Current Topics in Microbiology and Immunology
Published
2015
Pages
61-117
ISSN
  • 0070-217X
  • 2196-9965
Cited by
27
References
14
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells. https://app.cochat.ai/papers/10.1007/978-3-319-22834-1_3
The paper
Allday, M. J., Bazot, Q., & White, R. E. (2015). The EBNA3 Family: Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells. Current Topics in Microbiology and Immunology. https://doi.org/10.1007/978-3-319-22834-1_3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.